NTN. M. Tereshchenko

N. M. Tereshchenko

*This is an algorithmically generated author record based on publicly available information.

N. M. Tereshchenko has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinico-demographic characteristics and immunological cerebrospinal fluid markers in patients with headache and multiple sclerosis

    by N.M. Tereshchenko, V.S. Krasnov, N.A. Totolyan, E.V. Verbitskaya, A.V. Amelin

    Objective. To examine clinico-demographic characteristics, incidence and patterns of oligoclonal IgG in cerebrospinal fluid (CSF), concentrations of free light chains of immunoglobulin kappa (k-FLC), and total CSF protein in patients with multiple sclerosis (MS) with and without headache. Material and methods A retrospective single-center cohort study of patients with MS was performed between 2018 and 2024 at the Pavlov First St. Petersburg State Medical University. Medical records from 320 patients with MS were analyzed. Results. Among 320 patients with MS, 105 (32.8%) ones experienced headaches (H), including migraine (M) in 69 (21.6%), tension-type headache (TTH) in 19 (5.9%), and unclassified headache (UH) in 17 (5.3%) cases. M was more common in recurrent MS (19.1%) than in progressive MS (2.5%, p=0.006). TTH and UH did not demonstrate similar patterns. The incidence of type 2 IgG synthesis in CSF in the MS with M group was 79.31%, while in MS without headache — 64.42% (p=0.048). Levels of anti-FLC and total protein in CSF did not differ significantly between groups (p=0.395 and p=0.854, respectively). When comparing the incidence of type 2 IgG synthesis in CSF between groups for all headaches (M+TTH+ UH) and MS without headache, we found significant differences with higher incidence in the 1st group: 78.8% and 64.4%, respectively (p=0.021). Levels of anti-FLC and total protein in CSF were similar. Conclusion. Our data demonstrate high prevalence of M in patients with MS. Prevalence of M in remitting course of MS and high frequency of pathological synthesis of IgG in CSF in patients with any headache, and especially M, may indicate inflammatory mechanisms of headaches in some patients with MS. This justifies a prospective study on a large sample of patients with analysis of additional pathogenetically significant parameters.

  • Migraine in patients with multiple sclerosis: analysis of own data

    by N. M. Tereshchenko, A. V. Amelin, N. A. Totolyan, E. V. Verbitskaya

    Introduction. According to international publications, migraine (M) is more common in patients with multiple sclerosis (MS) than in the general population, while other types of primary headache (PH), including tension-type headache (TTH), do not have a similar tendency. There are several theories about the relationship between M and MS, but the substantiated mechanisms are currently unknown. The objective of our work was to analyze the data on the occurrence and characteristics of M in patients with MS. Methods and materials. A retrospective monocenter cohort study of patients with MS for the period 2018–2024 based on the Pavlov First Saint Petersburg State Medical University. Medical records of 168 patients with MS were analyzed. Results. The overall prevalence of PH in our cohort of patients was 36.9 %, including headache type M 22 %, TTH 6.6 %, unclassified headache (UH) 8.3 %, drug-induced headache (DIH) in the presence of any form of PH 6.5 %. M was significantly more common in the relapsing-remitting type of MS (RRMS) than in the primary and secondary progressive types (PPMS, SPMS) combined (p=0.031). The median EDSS (Expanded Disability Status Scale) disability scale in the group with M was 2 [2.0; 3.5], which is lower (p=0.046) than in the group of patients without headache 3.5 [2.0; 6.0]. Demographic characteristics and the use of disease-modifying drugs (DMARDS) did not differ significantly between the groups, and M was observed both before clinical manifestations of MS, at its manifestation, and developed after diagnosis. Conclusion. The obtained data demonstrate a high prevalence of M in MS. Patients predominantly with RRMS and a low level of disability represent a promising category for further study of the relationship between HD and demyelinating disease.

  • Open Access

    Efficacy of zolmitriptan nasal spray in adult patients with migraine

    by A. V. Amelin, I. S. Vaganova, M. I. Koreshkina, N. M. Tereshchenko

    Introduction. Migraine is a common disabling condition. Migraine patients require fast-acting drugs with high efficacy. Prior studies have demonstrated that zolmitriptan oral dosage forms (oral tablets) are highly effective in the treatment of migraine attacks.Aim. To evaluate the efficacy, timing of onset of therapeutic effect and tolerability of zolmitriptan nasal spray (Xsenza®) in the treatment of migraine.Materials and methods. A total of 39 patients aged 20 to 58 years with migraine were enrolled in a prospective, multicentre, observational study. Patients were included in a group to treat three consecutive migraine attacks with zolmitriptan nasal spray at a dose of 2.5 mg according to their habitual behaviour model that most closely reflects clinical practice. Efficacy endpoint (positive attack treatment outcome) was the generally accepted measure of reduction in cephalalgia intensity and concomitant autonomic symptoms (reduction in pain and autonomic symptoms from severe/moderate to mild/absence severity according to VAS) 2 hours after zolmitriptan inhalation.Results. The absence or mild intensity of headache was reported in 25% of patients 10 minutes (earliest assessment in that study) and in 28% of patients 30 minutes after administration of the drug. The proportion of patients with positive treatment outcomes in all three consecutive migraine attacks two hours after administration of zolmitriptan nasal spray 2.5 mg was 69.2%, 75% and 75%, respectively. Zolmitriptan nasal spray was well tolerated, while most adverse events were mild in severity and transient in nature.Conclusions. Zolmitriptan nasal spray (Xsenza®) is highly effective in the treatment of migraine attacks and has a rapid onset of action. The drug combines high efficacy and good tolerability.


  • Open Access

    Best practices in the use of human immunoglobulin preparations for intravenous administration in the treatment of rare neurological diseases

    by N. M. Tereshchenko, Ya. B. Kushnir, M. P. Abramova, A. A. Gotovchikov, V. S. Krasnov, A. Y. Sokolov, N. A. Totolyan, A. V. Amelin

    Aim. To describe best practices in using human normal immunoglobulin in patients with immune-mediated neurological disorders according to the data of one clinical center.Materials and methods. From 2016 to 2021, 20 patients with various autoimmune disorders of the peripheral and central nervous system were treated with human normal immunoglobulin at the Neurology Unit No.1 of Pavlov First Saint Petersburg State Medical University. Treatment efficacy was assessed by changes in the neurological examination data according to specialized scales for specific diseases or clinical manifestations (INCAT, QMGS, MoCA, EDSS). Safety of the therapy was assessed considering the instructions to the drug.Results. In the vast majority of patients, treatment allowed to stabilize the course of the disease or was accompanied by pronounced regression.Conclusion. The considered clinical cases of the use of human normal immunoglobulin preparations demonstrate the possibility of their use in the treatment of a number of autoimmune neurological diseases for unregistered indications.


  • Russian multicenter study of fixed combination of diclofenac and orphenadrine its efficacy and tolerance of in acute non-specific pain and radiculopathy relief

    by A.V. Amelin, V.A. Balyazin, O.S. Davydov, S.K. Zyryanov, D.V. Kiselev, O.V. Kurushina, L.A. Medvedeva, N.M. Tereshchenko, V.A. Shirokov, M.L. Kukushkin, et al.


  • Open Access

    Experience of using Rituximab in neurological practice (literature review and own observation)

    by Ya. B. Kushnir, N. M. Tereshchenko, M. P. Abramova, A. A. Gotovchikov, A. Yu. Polushin, V. S. Krasnov

    Currently, due to the lack of specific etiotropic therapy, rituximab is widely used for the treatment of most autoimmune diseases of the central and peripheral nervous system. Rituximab is a chimeric monoclonal antibody with specificity for CD20, the antigen found on the surface of normal and malignant B-lymphocytes. It is used mainly in hematological practice. It is used off-label for the treatment of neurological diseases. The world literature describes the use of rituximab for the treatment of such pathologies as autoimmune encephalitis, neuromyelitis optica spectrum disorder, multiple sclerosis, primary angiitis of the central nervous system, immune-mediated inflammatory polyneuropathy, myasthenia gravis, refractory to basic immunosuppressive therapy. This article provides an overview of the world literature on the use of rituximab in neurological practice, describes our own experience of its use on the basis of the Department of Neurology № 1 of Pavlov University (Saint Petersburg, Russia).